Novo Nordisk’s digital health deal with Glooko has yielded a new diabetes management app that the partners hope will enable users to better manage the condition.
The C4C app also includes relevant content and resources from Novo’s Cornerstones4Care personalised support programme.
David Moore, senior vice president of marketing at Novo Nordisk, said: “In today’s environment, in order to truly improve the prospects of the 29 million people with diabetes in the US, we must aspire towards leadership in digital health that complements our research and development expertise.
“That was the catalyst to our partnership with Glooko as well as IBM Watson Health and this milestone is just the beginning. Our companies share a common vision of empowering patients with ever improving digital health solutions,” he added.
The C4C app will initially enable people with diabetes to easily measure and track their blood glucose, activity and meals all in one place, and will sync a user’s blood glucose and activity data from the majority of currently available diabetes and exercise devices.
Rick Altiner, CEO of Glooko, said: “More people than ever are using mobile apps for chronic disease management and the apps, like the new C4C app, go beyond data capture or tracking to providing insights and recommendations based on that data.”
“Ultimately our digital health solution will help healthcare practitioners gain round-the-clock insight into heir patients, and empower people to better manage their diabetes.”
